A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

Daniel J. Wallace, William Stohl, Richard A. Furie, Jeffrey R. Lisse, James D. McKay, Joan T. Merrill, Michelle A. Petri, Ellen M. Ginzler, W. Winn Chatham, W. Joseph McCune, Vivian Fernandez, Marc R. Chevrier, Z. John Zhong, William W. Freimuth

Research output: Contribution to journalArticlepeer-review

400 Scopus citations

Fingerprint Dive into the research topics of 'A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus'. Together they form a unique fingerprint.

Medicine & Life Sciences